Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

Conditions

• Skin Diseases, Infectious

Interventions

• DRUG: Daptomycin
• DRUG: Standard of Care (SOC)

Sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)